Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
That’s why quetiapine “perhaps should not be considered a first-line maintenance treatment option in schizophrenia,” the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback